LY 4066434
Alternative Names: LY-4066434Latest Information Update: 01 Oct 2024
At a glance
- Originator Loxo Oncology
- Class Antineoplastics
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 23 Sep 2024 Eli Lilly and Company plans to initiated a phase Ia/Ib trial for Solid tumours (Late-stage disease, unresectable/Inoperable, Metastatic disease) (PO) (NCT06607185)
- 23 Oct 2023 Loxo Oncology plans to file an IND application for Cancer in 2024
- 13 Oct 2023 Pharmacodynamics and pharmacokinetics data from preclinical studies in Cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC -2023)